Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Electricity sector in Bolivia Electricity sector in Bolivia The electricity sector in Bolivia is dominated by the state-owned ENDE Corporation (Empresa Nacional de Electricidad), although the private Bolivian Power Company ("Compañia Boliviana de Energía Eléctrica"; COBEE) is also a major producer of electricity. ENDE had been unbundled into generation, transmission and distribution and privatized in the 1990s, but most of the sector was re-nationalized in 2010 (generation) and 2012 (transmission and distribution). The supply is dominated by thermal generation (65%), while hydropower (35%) has a smaller share in its generation mix compared to other South American countries. (Latin America and the Caribbean, or LAC,